A major milestone has been reached for Australians living with arthritis and musculoskeletal conditions, with the Australian Government announcing a new $100 million Medical Research Future Fund (MRFF) Mission dedicated to arthritis and musculoskeletal health. Nearly seven million Australians are affected by these conditions, including many people living with polymyalgia rheumatica (PMR) and giant cell arteritis (GCA). This landmark investment recognises the significant impact these diseases...

Our team has published a national survey of Australian rheumatologists examining how polymyalgia rheumatica (PMR) is diagnosed and managed across the country. Led by rheumatologist Dr Jessica Leung, the article titled "Experience of Australian rheumatologists managing polymyalgia rheumatica: results from a national survey" was published in the Internal Medicine Journal. Dr Leung's study found considerable variation in clinical practice, including differences in diagnostic approaches, access...

New results presented at the EULAR 2026 Congress suggest that baricitinib may help people with newly diagnosed polymyalgia rheumatica achieve remission while substantially reducing their reliance on glucocorticoids. In the Phase 3 JAK-SPARE trial, nearly two-thirds of patients receiving baricitinib achieved glucocorticoid-free remission within 16 weeks, compared with fewer than one in five patients receiving placebo. Patients treated with baricitinib also required significantly lower...